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Sowa-Staszczak, A.; Opalińska, M.;
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Abstract: Multiple neuroendocrine neoplasia type 1 (MEN1) is a rare genetic disorder with an auto-
somal dominant inheritance, predisposing carriers to benign and malignant tumors. The phenotype
of MEN1 syndrome varies between patients in terms of tumor localization, age of onset, and clinical
aggressiveness, even between affected members within the same family. We describe a heterogenic
phenotype of the MEN1 variant c.781C>T (LRG_509t1), which was previously reported only once
in a family with isolated hyperparathyroidism. A heterozygous missense variant in exon 4 of the
gene was identified in the sequence of the MEN1 gene, i.e., c.781C>T, leading to the amino acid
change p.Leu261Phe in a three-generation family. In the screened family, 5/6 affected members had
already developed hyperparathyroidism. In the index patient and two other family members, an
aggressive course of pancreatic neuroendocrine tumor (insulinoma and non-functioning neuroen-
docrine tumors) with dissemination was diagnosed. In the index patient, late diagnosis and slow
progression of the disseminated neuroendocrine tumor have been observed (24 years of follow-up).
The very rare variant of MEN1, LRG_509t1 c.781C>T /p.Leu261Phe (LRG_509p1), diagnosed within
a three-generation family has a heterogenic clinical presentation. Further follow-up of the family
members should be carried out to confirm the spectrum and exact time of clinical presentation.
Keywords: cascade genetic screening; hyperparathyroidism; multiple endocrine neoplasia type 1;
pancreatic neuroendocrine tumor; pituitary tumor
1. Introduction
Multiple neuroendocrine neoplasia type 1 (MEN1) is a rare, heterogeneous genetic
disorder with an autosomal dominant inheritance, predisposing the carrier to benign and
malignant tumors. The prevalence of MEN1 is estimated to be approximately 1:30,000 in
individuals, with no sex predominance [1]. The penetrance of the disease is very high and
increases with age (up to 95% by the age of 50 years). The phenotype of MEN1 syndrome
varies between patients in terms of tumor localization, age of onset, and clinical aggres-
siveness, even between affected members within the same family [2–8]. The most common
endocrinological manifestations are parathyroid adenoma, pancreatic neuroendocrine tu-
mor, and pituitary adenoma. Other characteristic non-endocrine features include cutaneous
lesions such as angiofibromas, collagenomas, and café au lait macules [1,9]. Most cases of
multiple endocrine neoplasia type 1 occur in a familial setting; however, in 10% of patients,
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de novo variants have been described and single reports of mosaic MEN1 alterations have
been noted [10,11]. The diagnosis of MEN1 syndrome can be clinically established based on
(i) the presence of two tumors typical of MEN1; (ii) the presence of one characteristic MEN1
tumor and one first-degree relative with a confirmed disease-associated MEN1 variant,
or (iii) cascade genetic screening in an asymptomatic carrier [12]. Genetic screening tests
should search for sequence variations or large deletions. Genetic screening is recommended
starting at the age of 5 years [13,14].
The MEN1 gene, located on chromosome 11q13, encodes the menin protein [15,16].
Menin directly regulates expression of the cyclin-dependent kinase-inhibiting (CKI) genes
CDKN1b (encoding p27) and CDKN2C (encoding p18). To date, over 1500 variants of
MEN1 have been described, including frameshift variants, nonsense variants, missense
variants, splice site variants, and large deletions. Additionally, patients with these variants
should be carefully monitored due to their uncertain clinical significance and heteroge-
neous presentation. [4,5]. In the present study, we describe a heterogenic phenotype
of the MEN1 variant c.781C>T, previously reported only once in a family with isolated
hyperparathyroidism [17].
2. Materials and Methods
Extraction of DNA from whole blood of the patients, which was collected on EDTA,
was performed using the NucleoSpin® Blood kit (Macherey-Nagel, Dueren, Germany).
All coding exons of MEN1 (LRG_509t1) were amplified using tiTaq DNA polymerase
(EurX, Gdansk, Poland) and 100 ng DNA in a 25-µL reaction in an Eppendorf MasterCycler
thermocycler. Following electrophoresis (Biometra Horizon 20.25 with a Consort EV243
power pack) on a 1% agarose gel stained with ethidium bromide, the obtained PCR
products were visualized by a gel documentation system with a UV transilluminator (UVP
GelDoc IT310). After purification of the PCR products through the use of a commercially
available kit (NucleoSpin® Gel and PCR Clean up, Macherey-Nagel, Dueren, Germany),
the fragments were sequenced using 25 ng of the purified PCR product and the BigDye®
Terminator v3.1 Cycle Sequencing Kit (LifeTechnologies, ThermoFisher Scientific, Waltham,
MA, USA), purified by ethanol precipitation. These fragments were then read on an
ABI3500 sequencer (Applied Biosystems, ThermoFisher Scientific, Waltham, MA, USA).
The obtained sequences were aligned to the appropriate reference using SeqScape software
(LifeTechnologies, ThermoFisher Scientific, Waltham, MA, USA). Further analyses were
performed using the UCSC Genome Browser (http://genome.ucsc.edu/, accessed on
24 July 2020) and associated links on the human GRCh38/hg38 genome assembly. Multiplex
ligation-dependent probe amplification (MLPA) analysis (MRC Holland probemix P017)
was performed according to the manufacturer’s recommendations in order to rule out large
deleterious events in the gene. PROVEAN (v1.1.3) and SIFT (v4.0.3) tools (provean.jcvi.org)
and the Bayes classifier-based MutationTaster prediction tool (www.mutationtaster.org)
(all accessed on 24 July 2020) were used for prediction of the identified variant’s impact on
the protein’s biological function.
3. Results
A large Polish family was identified in which three generations had a MEN1 variant
as confirmed by genetic testing. The index patient, II.3 of the pedigree (Figure 1), was
admitted to our Department at the age of 54 and MEN1 diagnosis was based on clinical
manifestations (Table 1). Genetic testing was performed in the index patient at the age of
61. Genetic screening revealed a MEN1 pathogenic variant in other five family members,
four of whom had clinical symptoms.
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Figure 1. Pedigree of a family with multiple neuroendocrine neoplasia type 1 (MEN1) syndrome. Generations available 
for the study are indicated by Roman numerals I–IV. Black symbols: affected subject. Grey symbol: MEN1 variant carrier. 
Squares indicate male; circles indicate female; the arrow indicates the index patient. The horizontal line in circles and 
squares indicates a negative MEN1 variant gene test, while a diagonal line in the square indicates that the patient was not 
alive at the time of the study. 
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roendocrine tumor was suspected based on biochemical as well as clinical data. A com-
puted tomography (CT) scan of the abdomen revealed a pancreatic tumor. The patient 
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Figure 1. Pedigree of a family with multiple neuroendocrine neoplasia type 1 (MEN1) syndrome.
Generations available for the study are indicated by Roman numerals I–IV. Black symbols: affected
subject. Grey symbol: MEN1 variant carrier. Squares indicate male; circles indicate female; the arrow
indicates the index patient. The horizontal line in circles and squares indicates a negative MEN1
variant gene test, while a diagonal line in the square indicates that the patient was not alive at the
time of the study.
Table 1. Clinical features of the proband and relatives.
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3.1. Index Patient
The index patient was a female born in 1953 and was the mother of two unaffected
children. She was first admitted in 1996 to the Internal Medicine Depart ent due to
symptomatic hypoglycemia, which she had observed for ten months. An insulin-secreting
neuroendocrine tumor was suspected based on biochemical as well as clinical data. A
computed tomography (CT) scan of the abdomen revealed a pancreatic tumor. The pa-
tient underwent surgical pancreatoduodenectomy (Traverso-Longmire procedure). An
insulin-secreting neuroendocrine tumor was confirmed by histopathology. Additionally,
in 1996, the patient underwent cholecystectomy due to cholecystolithiasis. During that
time, hypercalcemia was not found in the patient’s medical records; however, ultrasound
examination of the kidneys suggested nephrolithiasis. After surgery, the patient developed
diabetes, which was poorly controlled with intensive insulin therapy. In 1999, the patient
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underwent a total hysterectomy with bilateral salpingo-oophorectomy due to a myoma of
the uterus.
The diagnosis of primary hyperparathyroidism (PHPT) was confirmed in 2007. At this
point, the patient had already suffered from nephrolithiasis for several years. Ultrasound
examination of the neck revealed a nodular goiter and a single hypoechogenic mass in the
topography of the left inferior parathyroid gland. The patient underwent a partial strumec-
tomy and resection of the enlarged parathyroid. Parathyroid adenoma was identified via
histopathology. The patient was diagnosed with MEN1 syndrome based on the clinical
diagnostic criteria. Pituitary magnetic resonance imaging showed a normal pituitary gland
(size 12 × 6 × 14 mm) with no sign of focal lesions. In 2008, during the radiological follow-
up, abdominal CT scan revealed focal lesions—possible metastases—located ventrally to
the connection of the splenic and the inferior mesenteric vein, in the remaining part of the
duodenum, and in the mesenteric lymph nodes. The somatostatin receptor imaging (SRI)
with 99mTc result was negative. Repeat surgery was performed, with resection of masses in
the mesentery as well as those located near the splenic vessels. Histopathological analysis
revealed metastases of the neuroendocrine tumor infiltrating adipose tissue, Ki67 < 1%;
90% of the cells had positive staining for somatostatin receptor (SSTR) type 2, type 4, and
type 5, and 50% of the tumor cells showed positive staining for SSTR type 3. Post-operative
SRI detected no pathological accumulation of the tracer.
During a follow-up visit in 2008, biochemical relapse of primary hyperparathyroidism
was detected (parathormone (PTH) 163.8 pg/mL, total calcium concentration 2.81 mmol/l)
without any visible lesions in ultrasonography or single-photon emission computed tomog-
raphy/computed tomography (SPECT/CT) with technetium-99 m methoxyisobutylisoni-
trile (99mTc) Tc-MIBI. In 2011, repeat SPECT/CT showed a pathological accumulation of
99mTc-MIBI in the topography of the left lower parathyroid. In 2011, the patient underwent a
total parathyroidectomy, resulting in subsequent iatrogenic long-lasting hypoparathyroidism.
In 2017, a second relapse of the neuroendocrine tumor was observed; (68Ga) Ga-
DOTATATE positron emission tomography/computed tomography (PET/CT) revealed
the pathological expression of somatostatin receptors in an epigastric lymph node and in
the second segment of the liver. In 2018, abdominal CT detected hypodense focal lesions
in the liver and enlarged mesenteric lymph nodes (Figure 2a–c). Moreover, mesenteric
lymph nodes and a focal lesion in the liver hilum (size 18 × 15 mm) were detected. A
non-functional tumor (18 × 10 mm) was detected in the left adrenal gland. Magnetic
resonance imaging of the liver revealed lesions in the eighth segment (20 × 30 mm) and
the second segment (11 mm). These were suspected to be metastatic lesions.
Fluorine-18 fluorodeoxyglucose PET/CT (FDG-PET) revealed a metabolically active
region in the liver and in the mesogastric region, either in the small intestine or in a
lymph node. Subsequently, (68Ga) Ga-DOTATATE PET/CT was performed. In the liver,
no pathological accumulation of the tracer was found; however, lymph nodes along
the lesser curvature of the stomach showed pathological expression of SSTR. At this
point, the patient did not consent to any further invasive diagnostic procedures. Physical
examination revealed the presence of cutaneous collagenomas and hyperpigmented skin
lesions (Figure 2d).
The patient’s mother is 84 years old (patient I.2). Calcium and PTH concentrations
in serum are within the normal range. She suffers from chronic gastritis but is in good
general condition. The patient’s mother did not consent to genetic testing. The patient’s
father suffered from prostatic hyperplasia and died at the age of 84 due to a pulmonary
infection. Genetic testing was not performed. The index patient has two siblings: a brother
with MEN1 syndrome (patient II.4 in the pedigree) and a sister (patient II.1) who is in
good general condition. Her total calcium and PTH concentrations in serum are within the
normal range. Genetic testing has not yet been performed.
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Figure 2. Cli ical and radiological presentati n of the index patient. Transverse (a), axial (b), and sagittal (c) fused (68Ga)
Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) images of a pancreatic insulinoma
with metastases (arrows), cutaneous manifestations of MEN1 syndrome (d) with collagenoma, and hyperpigmented skin
lesions (arrows).
3.2. Patient II.4
T index patie t’s brother was born in 1955 and is the father of fiv children, two of
whom are u affected. He was first admitted to the Endocrinology Department in 2015 and
MEN1 syndrome was confirmed via familial genetic screening. During the patient’s first
endocrinological evaluation, hypercalcemia (2.7 mmol/L) and elevated PTH (230 pg/mL)
were detected. A nodular goiter and an enlarged right upper parathyroid gland were
seen in the thyroid ultrasound examination. The right lobe and the isthmus as well as
the parathyroid gland were resected in 2016. Histopathological examination revealed
parathyroid adenoma; however, malignancy of the thyroid gland was not detected. Since
the surgery, calcium concentration and PTH l vels have been within the normal range and
the patient has no signs or symptoms of nephrolithiasis or osteoporosis. Multiple MRI
examinations performed during follow-up visits (most recently in 2017) did not detect any
focal lesions of the pituitary gland or excessive hormone secretion. An abdominal CT from
2016 revealed a 25-mm tumor of the uncinate process of the pancreas. Subsequent SRI
confirmed an abnormal accumulation of the tracer in this location. In 2017, the patient did
not consent to endoscopic ultrasound nor to surgical resection of the pancreatic lesion. The
patient did not attend any follow-up visits until October 2019, when another abdominal
CT was performed. Imaging revealed that the pancreatic lesion remained stable; however,
in (68Ga) Ga-DOTATATE PET/CT, the lesion showed intense accumulation of the tracer
(SUVmax 52). Additionally, pathological expression of the somatostatin receptors (SUVmax
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3.32) in the marrow cavity of the proximal 1/3 of the femur was discovered. Subsequent
CT confirmed the presence of a focal lesion in this location (32 mm), which was suspected
to be metastatic. Additionally, suspicious lesions with pathological expression of the
somatostatin receptors were discovered in the femur and tibia. The patient did not consent
to any further diagnostic procedures.
3.3. Patient III.3
A daughter of the index patient’s brother was born in 1979 with congenital hypoacusia
and was identified as carrier of a MEN1 during familial screening. In 2014, she underwent
a urological procedure due to nephrolithiasis in the right kidney and was subsequently
diagnosed with primary hyperparathyroidism. A subtotal parathyroidectomy was per-
formed in 2014. In 2018, the patient underwent a partial thyroidectomy due to presence of
a nodular goiter. During a follow-up visit in 2019, CT showed a 5-mm hypodense focal
lesion in the corpus of the pancreas. A similar 4-mm lesion was found in the uncinate
process. Imaging follow-up studies of the lesions and careful clinical and biochemical
assessments have been scheduled. Additionally, physical examination revealed multiple
cutaneous angiofibromas on the face and hyperpigmented skin lesions (Figure 3.) This
patient has two daughters, both of whom are negative for MEN1.
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Figure 3. Cutaneous angiofibromas of patient III.3 in the pedigree (arrows).
3.4. Patient III.5
A son of the index patient’s brother, born in 1980, was diagnosed with MEN1 syn-
drome via cascade genetic screening. Since 2014, he had been suffering from nephrolithiasis
and underwent percutaneous nephrolithotomy. Hypercalcemia in the course of primary
hyperparathyroidism was confirmed and the patient underwent parathyroidectomy with
resection of the upper right, lower right, and lower left parathyroid glands in April 2015,
wh c subsequently resulted in iatrogenic hypoparathyroidism. His o thological analysi
confirmed the presence of parathyroid odular hyperplasia. In 2014, bilateral adrenal
tumors were detected in abdominal CT (24 mm in the left adrenal gland and 5 mm in
the right, both characterized by radiological features of an adenoma), with no excessive
hormonal function. Additionally, CT confirmed the presence of a pancreatic cyst, which
was left in place for radiological follow-up. In 2015, MRI revealed a pituitary microade-
noma, clinically and biochemically silent. During a follow-up visit in 2016, abdominal CT
revealed a round 8-mm tumor with calcifications in the corpus of the pancreas (Figure 4a).
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Figure 4. Radiological presentation of patient III.4 in the pedigree. Transverse CT image of pancreas
with calcifications (a) and lung metastasis in axial (b) and transverse (c) CT (arrows).
In November 2017, (68Ga) Ga-DOTATATE PET/CT was performed. It revealed multi-
ple focal accumulations of the tracer in the pancreas, with the most prominent one observed
within the pancreatic corpus (SUVmax 22.8), located in the topography of a previously
described calcified tumor, and a probable metastasis in the left lung (SUVmax 6.54). In
January 2018, due to dissemination of the neuroendocrine tumor, treatment with Lanreotide
autogel at 120 mg s.c./4 weeks was initiated with good patient tolerance. In December
2018, an endoscopic ultrasound was performed. Histopathological examinatio of the
samples revealed the presence of a probable neuroendoc ine tumor (synapto hysin+,
ch omograni +). In January 2020, follow-up CT revealed a partial regression of the pancre-
atic lesions, while the pancreatic neuroendocrine tumors and metastatic lung lesion were
stable with no further progression (Figure 4b,c). Careful follow-up has been scheduled.
Non-endocrine manifestations were seen as multiple cutaneous collagenomas.
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This patient has three sons. Two are unaffected, while one is an asymptomatic carrier
of the familial MEN1 variant, which was diagnosed at the age of 7 years.
3.5. Patient III.9
A daughter of the index patient’s brother, born in 1991, was diagnosed at the age
of 23 with MEN1 syndrome via cascade genetic screening. At the time of diagnosis,
asymptomatic hypercalcemia was noted and primary hyperparathyroidism was confirmed.
She underwent total resection of three parathyroid glands in 2015. During a follow-up visit
in 2020, abdominal CT revealed two pancreatic lesions (17 mm and 15 mm). Subsequently,
endoscopic ultrasound-guided fine-needle aspiration biopsy of the pancreas was performed.
Histopathological examination revealed the presence of a neuroendocrine tumor (CD56-,
Ki67 1%, synaptophysin+, chromogranin+). Radiological follow-up has been scheduled. In
addition, the patient has multiple cutaneous collagenomas.
3.6. Genetic Results
A heterozygous missense variant in exon 4 was identified in the sequence of the
MEN1 gene (LRG_509), i.e., c.781C>T, leading to the amino acid change p.Leu261Phe at
the protein level. This variant has been registered in the NCBI dbSNP with the identifier
rs878855198. Based on criteria provided by a single submission to NCBI ClinVar, this variant
(ID 241826) is classified as having uncertain clinical significance. In the LOVD database (ID
MEN1_000346), this alteration has no assigned clinical classification. In the UMD-MEN1
database, there are three entries for this variant (UMD_ID 557, 558, and 595), two of which
relate to samples derived from members of one family. In all three cases, the variation has
been classified as “causal”. The variant is located in a phylogenetically conserved region,
and leucine at position 261 of the protein is, itself, highly conserved (Figure 5). Predictions
performed through the use of bioinformatics tools generate consistent results. PROVEAN
classifies this variant as “deleterious” (score −2.86), SIFT classifies this as “damaging”
(score 0.011), and MutationTaster classifies this as “disease-causing” (with a probability
of >0.999).
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4. Discussion
Our study describes the diverse outcomes (aggressive and benign) of a very rare
MEN1 variant within the same three-generation family. In this family, 5/6 affected mem-
bers have already developed hyperparathyroidism, with the earliest age at presentation
being 23 years, while the oldest presented at the age of 59 years. The youngest family
member was confirmed to carry the familial variant at the age of 7. This family mem-
ber is now 11 years of age and has been asymptomatic up until this point. Three of the
family members have shown an aggressive course of the disease with dissemination of
pancreatic neuroendocrine tumors; however, the index patient was diagnosed relatively
late and her disease progression is categorized as very slow (24 years up until now). In
only one affected family member, pituitary microadenoma was detected at the time of di-
agnosis (at age 34) along with other manifestations of the syndrome (hyperparathyroidism,
non-functioning pancreatic tumor). To date, the MEN1 LRG_509 c.781C>T (p.Leu261Phe)
variant has been described in one family presenting with a mild phenotype, with iso-
lated hyperparathyroidism reported as a gene variant with uncertain significance [4,5].
In the literature, there are several reports of MEN1 alterations related only to isolated
hyperparathyroidism, while the same variant in other families results in different pheno-
types with other MEN1-associated tumors [4,5]. Despite the large number of identified
variants in MEN1, genotype–phenotype correlation has not been estimated due to the
heterogeneity of the disease. Previous studies of unrelated patients with the same variant
demonstrated the variable clinical expression of MEN1 characteristic tumors. Even case re-
ports of monozygotic twins have reported different phenotypes of MEN1 syndrome [18,19].
It is hypothesized that environmental factors could have an influence on epigenetic effects
and, therefore, lead to various clinical outcomes. Patients diagnosed with MEN1 syndrome
should be treated and managed according to current guidelines [12]. Screening of the
presented family was scheduled at the time of diagnosis of the index patient; however,
these examinations were performed in most of the family members in adulthood, after a
long delay. Screening in childhood, as suggested by guidelines, allowed for identification
of an asymptomatic carrier (patient IV.4) and for scheduling of the appropriate follow-up.
MEN1 patients have a decreased life expectancy and worse clinical outcomes using cur-
rently available treatment when compared to sporadic cases with corresponding tumors.
MEN1-associated tumors are often multifocal and more aggressive, with distant metastases,
and are, therefore, resistant to treatment [20,21].
The earliest and most common MEN1-related feature is primary hyperparathyroidism
due to parathyroid hyperplasia or parathyroid adenoma. Up to the age of 50 years, hyper-
parathyroidism shows almost 100% penetrance. Conversely, among all patients diagnosed
with PHPT, MEN1 variants are observed in 1–18% of patients [22]. Hyperparathyroidism
associated with MEN1 is more aggressive (e.g., a greater decline in bone mineral density as
well as urolithiasis at a young age) [23]. In addition, multiple involvement of the gland
and higher recurrence rate have been observed in comparison to sporadic cases (55% vs.
4–16%) [24]. Four affected members in our study presented with PHPT as a first manifesta-
tion and developed urolithiasis at a young age. In the index patient, the first manifestation
was the presence of an insulinoma, while cholelithiasis and urolithiasis preceded the di-
agnosis of hypercalcemia. In the presented family, urolithiasis and cholelithiasis without
hypercalcemia preceded the diagnosis of hyperparathyroidism by several years. Therefore,
in the case of MEN1-related tumors, urolithiasis, or cholelithiasis without hypercalcemia,
should raise a suspicion of PHPT and lead to further investigation. Pancreatic neuroen-
docrine tumor is the second most common MEN1-related tumor and is present in 30–80%
of MEN1 patients; however, post-mortem studies showed a higher prevalence of 80–100%.
Ten percent of all pancreatic neuroendocrine tumors (pNETs) occur in the course of MEN1
syndrome [25]. The most common pNETs are non-functioning tumors (20–55% of MEN1
cases) [26]. Insulinomas occur in approximately 20–30% of cases, with a metastatic process
being observed in 4–14% of MEN1 patients [12,27,28]. The diagnosis of an insulinoma can
be challenging. In some cases, especially if no visible pancreatic lesion is observed, ad-
Genes 2021, 12, 512 10 of 12
vanced imaging techniques are required to detect the insulinoma [29]. In the index patient,
the presence of an insulinoma was confirmed at the age of 43, while dissemination was
detected at the age of 54. In addition, patients II.4 and III.5 presented with disseminated
non-functional NETs. In patients III.3 and III.9, non-functional pancreatic NETs remain
monitored at follow-up visits. The future treatment options depend on the course of the
disease. Surgery, peptide receptor radionuclide therapy (PPRT), and pharmacotherapy are
taken into consideration.
Pituitary tumors associated with MEN1 occur mostly in the fourth decade of life [20,21].
Prolactinoma is the most frequent pituitary manifestation; however, non-functioning pitu-
itary adenomas were predominantly detected by screening and were stable lesions [30].
A non-functioning pituitary microadenoma in patient III.5 was confirmed at the time
of MEN1 diagnosis. Non-functioning adrenocortical tumors were present in 2/6 of the
affected patients. Characteristic MEN1-related skin lesions (angiofibromas, collagenomas,
hyperpigmentation) were present in all of the screened family members. Nodular goiter
was present in 4/6 of the family members. Careful skin examination and diagnostics
for other tumors should be performed in all suspected MEN1 patients. The association
between thyroid disease and MEN1 remains controversial. In the earlier studies, nodular
goiters were linked to MEN1, while the more recent ones show that the rate of concurrence
of a thyroid incidentaloma is comparable in MEN1-positive and -negative patients [31].
Patient III.3 presented with hypoacusia. Thus far, there are no published reports of MEN1
and hypoacusia; however, various syndromic diseases associated with hearing loss have
been reported [32,33].
A limitation of our study is the fact that family members of the index patient were
not followed-up prospectively but were diagnosed at a certain point in time, long after the
index patient was diagnosed. Therefore, the exact onset of the MEN1 manifestations could
not be established. The delay in the cascade genetic screening resulted from a delayed
transfer of information about the genetic background of the disease between the family
members. The probable psychological barriers which hinder the sharing of information
about genetic diseases need further investigation and support [34].
5. Conclusions
The very rare variant of MEN1, LRG_509t1 c.781C>T /p.Leu261Phe (LRG_509p1),
diagnosed within a three-generation family, has a heterogenic clinical presentation. This
included the presence of previously unreported neuroendocrine tumors in selected family
members. Further follow-up of the family members should be performed to confirm the
spectrum and exact time of clinical presentation of this alteration.
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type 1 in Poland: A two center experience. Endokrynol. Pol. 2019. [CrossRef] [PubMed]
8. Godlewska, M.; Boguslawska, A.; Nowak, A.; Skalniak, A.; Sowa-Staszczak, A.; Gilis-Januszewska, A.; Hubalewska-Dydejczyk,
A. Acromegaly and late-onset primary hyperparathyroidism in a female with a rare MEN1 gene variant of yet undetermined
clinical significance (p.Val167Ala). Endokrynol. Pol. 2020, 71, 579–580. [CrossRef] [PubMed]
9. Thakker, R.V. Multiple endocrine neoplasia type 1. Indian J. Endocrinol. Metab. 2012, 16, 272.
10. Mauchlen, R.; Carty, D.; Talla, M.; Drummond, R. Multiple endocrine neoplasia type 1 (MEN1) mosaicism caused by a c.124G>A
variant in the MEN1 gene. Endocr. Abstr. 2019. [CrossRef]
11. Beijers, H.J.B.H.; Stikkelbroeck, N.M.L.; Mensenkamp, A.R.; Pfundt, R.; van der Luijt, R.B.; Timmers, H.J.L.M.; Hermus, A.R.M.M.;
Kempers, M.J.E. Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. Eur. J.
Endocrinol. 2019, 180, K15–K19. [CrossRef] [PubMed]
12. Thakker, R.V.; Newey, P.J.; Walls, G.V.; Bilezikian, J.; Dralle, H.; Ebeling, P.R.; Melmed, S.; Sakurai, A.; Tonelli, F.; Brandi, M.L.
MEN1 2012 Guideline. J. Clin. Endocrinol. Metab. 2012. [CrossRef]
13. Cavaco, B.M.; Domingues, R.; Bacelar, M.C.; Cardoso, H.; Barros, L.; Gomes, L.; Ruas, M.M.A.; Agapito, A.; Garrao, A.;
Pannet, A.A.J. Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline
deletions. Clin. Endocrinol. (Oxf.) 2002, 56, 465–473. [CrossRef] [PubMed]
14. Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24, 355–370. [CrossRef]
15. Chandrasekharappa, S.C.; Guru, S.C.; Manickam, P.; Olufemi, S.E.; Collins, F.S.; Emmert-Buck, M.R.; Debelko, L.V.; Zhuang, Z.;
Lubensky, I.A.; Liotta, L.A. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276, 404–406.
[CrossRef] [PubMed]
16. Lemmens, I.; van de ven Wim, J.M.; Kas, K.; Zhabg, C.X.; Giraud, S.; Waotot, V.; Buisson, N.; de Witte, D.; Salandre, J.; Lenoir, G.
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum. Mol. Genet. 1997, 6, 1177–1183. [CrossRef] [PubMed]
17. Tham, E.; Grandell, U.; Lindgren, E.; Toss, G.; Skogseid, B.; Nordenskjöld, M. Clinical testing for mutations in the MEN1 gene in
Sweden: A report on 200 unrelated cases. J. Clin. Endocrinol. Metab. 2007, 92, 3389–3395. [CrossRef]
18. Concolino, P.; Rossodivita, A.; Carrozza, C.; Rafaelli, M.; Lombardi, C.P.; Rigante, D.; Pitocco, D.; Stabile, A.; Bellantone, R.;
Zuppi, C. A novel MEN1 frameshift germline mutation in two Italian monozygotic twins. Clin. Chem. Lab. Med. 2008, 46, 824–826.
[CrossRef]
19. Flanagan, D.E.H.; Armitage, M.; Clein, G.P.; Thakker, R.V. Prolactinoma presenting in identical twins with multiple endocrine
neoplasia type 1. Clin. Endocrinol. (Oxf.) 1996, 45, 117–120. [CrossRef] [PubMed]
20. Vergès, B.; Boureille, F.; Goudet, P.; Murat, A.; Beckers, A.; Sassolas, G.; Cougard, P.; Chambe, B.; Montvernay, C.; Calender, A.
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study. J. Clin. Endocrinol. Metab.
2002, 87, 457–465. [CrossRef]
21. Trouillas, J.; Labat-Moleur, F.; Sturm, N.; Kujas, M.; Heymann, M.F.; Figarella-Branger, D.; Patey, M.; Mazucca, M.; Decullier, E.
Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): A case-control study in a series of 77
patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 2008, 32, 534–543. [CrossRef] [PubMed]
22. Goudet, P.; Dalac, A.; Le Bras, M.; Cardot-Bauters, C.; Nicolli, P.; Levy-Bohbot, N.; du Boullay, H.; Bertagna, X.; Ruszniewski, P.
MEN1 disease occurring before 21 years old: A 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines.
J. Clin. Endocrinol. Metab. 2015, 100, 1568–1577. [CrossRef] [PubMed]
Genes 2021, 12, 512 12 of 12
23. Lourenço, D.M.; Toledo, R.A.; Mackowiak, I.I.; Coutinho, F.L.; Cavalcanti, M.G.; Correia-Deur, J.E.M.; Montenegro, F.;
Siqueira, S.A.C.; Margarido, L.C.; Machado, M.C. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation,
clinical features, and bone mineral density profile. Eur. J. Endocrinol. 2018, 159, 259–274. [CrossRef] [PubMed]
24. Rizzoli, R.; Green, J.; Marx, S.J. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up
of serum calcium levels after parathyroidectomy. Am. J. Med. 1985, 78, 467–474. [CrossRef]
25. Marx, S.J.; Simonds, W.F. Hereditary hormone excess: Genes, molecular pathways, and syndromes. Endocr. Rev. 2005, 26, 615–661.
[CrossRef] [PubMed]
26. Brandi, M.L.; Gagel, R.F.; Angeli, A.; Bilezikian, J.P.; Beck-Peccoz, P.; Bordi, C.; Conte-Devolx, B.; Falchetti, A.; Gheri, R.G.;
Libroia, A. Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. 2001, 86, 5658–5671.
[CrossRef]
27. Kaltsas, G.; Caplin, M.; Davies, P.; Ferone, D.; Garcia-Carbonero, R.; Grozinsky-Glasberg, S.; Horsch, D.; Tiensuu Janson, E.;
Kianmanesh, R.; Kos-Kudla, B. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and
Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology 2017, 105, 245–254. [CrossRef]
28. Baudin, E.; Caron, P.; Lombard-Bohas, C.; Tabarin, A.; Mitry, E.; Reznick, Y.; Taieb, D.; Pattou, F.; Goudet, P.; Vezzosi, D.; et al.
Malignant insulinoma: Recommendations for workup and treatment. Presse Med. 2014, 43, 645–659. [CrossRef]
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